Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Share:
Related LLY
Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In
The Vetr community has downgraded $LLY to 3-Stars (Vetr)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

DateFirmActionFromTo
Dec 2015Leerink PartnersMaintainsOutperform
Dec 2015Atlantic EquitiesInitiates Coverage onOverweight
Dec 2015Deutsche BankUpgradesHoldBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Get Benzinga's Newsletters